SCHEMBL21484872

SCHEMBL21484872

N#CCC(=O)Nc1nc(-c2ccc(C(F)(F)F)cn2)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.53
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GSTO1 P78417 1/20 0.45
MRE11 P49959 1/20 0.43
AGPAT2 O15120 1/20 0.42
NPY5R Q15761 1/20 0.41
KDM4A O75164 1/20 0.40
KDM4B O94953 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484654 0.85 ABL1 (0.65) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL21484623 0.83 ABL1 (0.54) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL21484621 0.83 ABL1 (0.56) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL21484749 0.80 ABL1 (0.53) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL21484682 0.78 ALDH1A1 (0.64) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL21484657 0.76 MRE11 (0.58) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL21484647 0.76 ABL1 (0.65) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL9188600 0.76 RAB9A (0.53) KDM4ENPC1RAB9ASMN1; SMN2NPY5R
SCHEMBL21484902 0.75 ABL1 (0.64) ABL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL21484713 0.73 ABL1 (0.68) ABL1KDM4EALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 ABL1 2243/4885KDM4E 1848/4885ALDH1A1 2267/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 ABL1 2243/4885KDM4E 1848/4885ALDH1A1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.